The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Open accessAbstract
Purpose: To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma. Patients and Methods: Patients with recurrent glioblastoma were treated with bevacizumab 10 mg/kg every 2 weeks. After tumor progression, patients were immediately treated with bevacizumab in combination with irinotecan 340 mg/m 2 or 125 mg/m 2 every 2 weeks, depending on use of enzyme-inducing antiepileptic drugs. Complete patient evaluations were repeated every 4 weeks. Results: Forty-eight heavily pretreated patients were accrued to this study. Thromboembolic events (12.5%), hypertension (12.5%), hypophosphatemia (6%), and thrombocytopenia (6%) were the most common drug-associated adverse events. Six patients (12.5%) were removed from study for drug-associated toxicity (five thromboembolic events, one bowel perforation). Thirty-four patients (71%) and 17 patients (35%) achieved radiographic response based on Levin and Macdonald criteria, respectively. Median progression-free survival (PFS) was 16 weeks (95% CI, 12 to 26 weeks). The 6-month PFS was 29% (95% CI, 18% to 48%). The 6-month overall survival was 57% (95% CI, 44% to 75%). Median overall survival was 31 weeks (95% CI, 21 to 54 weeks). Early magnetic resonance imaging response (first 96 hours and 4 weeks) was predictive of long-term PFS, with the Levin criteria being more predictive than Macdonald criteria. Of 19 patients treated with bevacizumab plus irinotecan at progression, there were no objective radiographic responses. Eighteen patients (95%) experienced disease progression by the second cycle, and the median PFS was 30 days. Conclusion: We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
Lamborn, K. R., Chang, S. M., & Prados, M. D. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000620 · Cited by 546
Factors influencing survival in high-grade gliomas
Buckner, J. C. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.031 · Cited by 443
Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K. L., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 421
Self-citationBallman, K. V., Buckner, J. C., Brown, P. D., Giannini, C., Flynn, P. J., LaPlant, B. R., & Jaeckle, K. A. (2007) · Neuro-Oncology · doi:10.1215/15228517-2006-025 · Cited by 314
Prados, M. D., Lamborn, K., Yung, W. K. A., Jaeckle, K., Robins, H. I., Mehta, M., Fine, H. A., Wen, P. Y., Cloughesy, T., Chang, S., et al. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-010 · Cited by 254
Self-citationMeasuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria
Park, J. O. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg093 · Cited by 222
Self-citationCriteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J.-P., & Wilson, C. B. (1977) · Journal of Neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Takahashi, J. A., Fukumoto, M., Igarashi, K., Oda, Y., Kikuchi, H., & Hatanaka, M. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.76.5.0792 · Cited by 171
Stefanik, D. F., Fellows, W. K., Rizkalla, L. R., Rizkalla, W., Stefanik, P. P., DeLeo, A. B., & Welch, W. C. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1013329832067 · Cited by 115
Batchelor, T. T., Gilbert, M. R., Supko, J. G., Carson, K. A., Nabors, B., Grossman, S. A., Lesser, G. J., Mikkelsen, T., & Phuphanich, S. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000218 · Cited by 114
Maxwell, M., Naber, S. P., Wolfe, H. J., Hedley‐Whyte, E. T., Galanopoulos, T., Neville-Golden, J., & Antoniades, H. N. (1991) · PubMed · Cited by 113
Therasse, P., Cesne, A. L., Glabbeke, M. M. V., Verweij, J., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.005 · Cited by 58
Cited by
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Metadata
- Authors
- Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., Park, J., Albert, P. S., & Fine, H. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 740-745
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170367762
- Cited by
- 1,577
- References
- 19
- FWCI
- 42.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.